
The collaboration aims to propose and elevate the focus on unmet needs with a holistic approach to women's health

The company’s currently ongoing Phase IIb pre-pivotal clinical study assesses the safety and efficacy of the IUB™ SEAD

This week we meet Keren Leshem, Ocon Healthcare CEO

The Isareli firm uses intrauterine drug-delivery technology to improve women’s health

According to the latest data from the Office for National Statistics, alcohol-specific deaths in females equate to 10.3 deaths per 100,000 women. It’s not just a...

New research is calling for a radical shift in how society addresses miscarriage, urging a move beyond traditional anti-stigma interventions. Scores of celebrities and public figures...

The women’s health company OCON Therapeutics has secured US$10m in funding to address uterine disorders. OCON aims to develop new drug delivery systems for treating some...

The femtech market is expected to reach US$50bn by 2025, but health inequalities remain. In our first FemTech World x HealthTech World roundtable, five leading experts...

Intrauterine drug-delivery technology aims to improve women’s health and quality of life with ball-shaped device